Prostate-specific membrane antigen expression in intracranial lesions - a review of the primary, metastatic, and nonneoplastic lesions

Kacper Pełka; Aleksandra Bodys-Pełka; Jolanta Kunikowska

doi:10.5603/nmr.97019

Prostate-specific membrane antigen expression in intracranial lesions - a review of the primary, metastatic, and nonneoplastic lesions

Nucl Med Rev Cent East Eur. 2023;26(0):134-142. doi: 10.5603/nmr.97019.

Authors

Kacper Pełka^{1

2}, Aleksandra Bodys-Pełka³, Jolanta Kunikowska⁴

Affiliations

¹ Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland. kacper.pelka@wum.edu.pl.
² Laboratory of Center for Preclinical Research, Department of Methodology, Medical University of Warsaw, Warsaw, Poland. kacper.pelka@wum.edu.pl.
³ Doctoral School, Medical University of Warsaw, Warsaw, Poland.
⁴ Department of Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland.

PMID: 37987378
DOI: 10.5603/nmr.97019

Abstract

Prostate-specific membrane antigen (PSMA) is a membrane protein originally discovered in prostate cancer cells. It is widely used at all stages of prostate cancer diagnosis. Several studies have highlighted its possible wide application in other cancers. This review discusses the potential use of positron emission tomography with labelled PSMA for the diagnosis or differentiation of intracranial lesions. Given the numerous reports on the usefulness of PSMA in the diagnosis of brain tumours of glial origin, the focus is on lesions of a different aetiology.

Keywords: GBM; PET/CT; PSMA; brain metastases; glial tumours; intracranial lesions.

Publication types

Review

MeSH terms

Gallium Radioisotopes
Humans
Male
Positron Emission Tomography Computed Tomography / methods
Positron-Emission Tomography / methods
Prostate* / metabolism
Prostate* / pathology
Prostatic Neoplasms* / diagnostic imaging

Substances

Gallium Radioisotopes